Table 3.
Multivariate analysis of prognostic factors for OS and PFS of patients with DLBCL
| Variate | OS | PFS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Age | 1.38 | 1.69–9.40 | < 0.01 | 0.39 | 0.87–2.51 | 0.15 |
| Clinical stage | − 0.39 | 0.22–2.06 | 0.57 | 0.69 | 1.23–3.23 | 0.01 |
| B symptoms | − 0.93 | 0.12–1.35 | 0.63 | 0.45 | 0.97–2.56 | 0.07 |
| Spleen involvement | − 0.05 | 0.24–3.87 | 0.95 | 0.34 | 0.74–2.67 | 0.30 |
| IPI | 1.01 | 0.59–12.70 | 0.20 | 0.02 | 0.51–2.04 | 0.96 |
| LDH | 0.29 | 0.49–3.67 | 0.57 | 0.24 | 0.76–2.15 | 0.35 |
| β2-MG | 0.02 | 0.33–3.18 | 0.98 | – | ||
| Rituximab | − 0.13 | 0.34–2.26 | 0.80 | – | ||
| CR after first-line chemotherapy | − 1.54 | 0.09–0.49 | < 0.01 | − 0.24 | 0.48–1.27 | 0.33 |
| PD-L1 expression in tumor cells | 1.40 | 1.61–10.23 | < 0.01 | 0.46 | 1.00–2.51 | 0.05 |
IPI international prognostic index, LDH lactate dehydrogenase, β2-MG β2-microglobulin, CR complete remission, PD-L1 programmed cell death ligand 1, – not included